Drug Trial Radar · NCT02343042
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Last checked: Nov 19, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Oct 2015
Primary completion
Apr 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- Karyopharm Therapeutics IncIndustry
- Sponsor type
- Industry
- Collaborators
- Bristol-Myers Squibb
- First posted
- Jan 21, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to be evaluated are: * Arm 1: Selinexor + dexamethasone + pomalidomide (SPd); enrollment complete * Arm 2: Selinexor + dexamethasone + bortezomib (SVd); enrollment complete * Arm 3: Selinexor + dexamethasone + lenalidomide (SRd) in RRMM; enrollment complete * Arm 4: Selinexor + dexamethasone + pomalidomide + bortezomib (SPVd); enrollment complete * Arm 5: Selinexor + dexamethasone + daratumumab (SDd); enrollment complete * Arm 6: Selinexor + dexamethasone + carfilzomib (SKd); enrollment complete * Arm 7: Selinexor + dexamethasone + lenalidomide (SRd) in NDMM; enrollment complete * Arm 8: Selinexor + dexamethasone + ixazomib (SNd); enrollment complete * Arm 9: Selinexor + dexamethasone + pomalidomide + elotuzumab (SPEd); enrollment complete * Arm 10: Selinexor + dexamethasone + belantamab mafodotin (SBd); enrollment complete * Arm 11: Selinexor + dexamethasone + pomalidomide + daratumumab (SDPd); enrollment complete * Arm 12: Selinexor + dexamethasone + mezigdomide (SMd); actively recruiting Selinexor pharmacokinetics: * PK Run-in (Days 1-14): Starting in protocol version 8.0, patients enrolled to any arm in the Dose Escalation Phase (i.e., Arm 4 \[SPVd\], Arm 6 \[SKd\], Arm 8 \[SNd\], Arm 9 \[SPEd\], Arm 10 \[SBd\], and Arm 11 \[SDPd\]) will also first be enrolled to a pharmacokinetics (PK) Run-in period until 9 patients have been enrolled to this period to evaluate the PK of selinexor before and after co-administration with a strong CYP3A4 inhibitor. This run-in period does not apply to Arm 12 (SMd).
Conditions
- Multiple Myeloma
Interventions
SelinexorDrug
Oral tablets
DexamethasoneDrug
Oral tablets
LenalidomideDrug
Oral capsule
PomalidomideDrug
Oral tablets
BortezomibDrug
Subcutaneous Injection (single use vial)
DaratumumabDrug
Intravenous Infusion
CarfilzomibDrug
Intravenous infusion
IxazomibDrug
Oral capsule
ElotuzumabDrug
Intravenous infusion
ClarithromycinDrug
Tablets
Belantamab MafodotinDrug
Intravenous infusion
MezigdomideDrug
Oral Capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 (Dose-escalation): Maximum Tolerated Dose (MTD)Time frame: 12 months
- Phase 1 (Dose-escalation): Recommended Phase-2 dose (RP2D)Time frame: 12 months
- Phase 1 (Dose-escalation): Maximum Plasma Concentration (Cmax) of SelinexorTime frame: Pre-dose, 1 hour, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post-dose on Day 1 (without clarithromycin) and Day 8 (with clarithromycin)
- Phase 1 (Dose-escalation): Area Under the Concentration-time Curve From Time Zero to the Last Non-zero Concentration (AUC0-t) of SelinexorTime frame: Pre-dose, 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post-dose on Day 1 (without clarithromycin) and Day 8 (with clarithromycin)
- Phase 1 (Dose-escalation): Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) (AUC0-inf)Time frame: Pre-dose, 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post-dose on Day 1 (without clarithromycin) and Day 8 (with clarithromycin)
- Phase 2 (Expansion): Overall response rate (ORR)Time frame: 12 months
- Phase 2 (Expansion): Duration of response (DOR)Time frame: 12 months
- Phase 2 (Expansion): Clinical Benefit Rate (CBR)Time frame: 12 months
Locations
25 sites in 2 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona · Active not recruiting
Jonnsson Comprehensive Cancer Center / University of Los Angeles
Los Angeles, California · Active not recruiting
Sarah Cannon-Colorado Blood Cancer Institute
Denver, Colorado · Withdrawn
Massachusetts General Hospital
Boston, Massachusetts · Completed
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
University of Nebraska Medical Center
Omaha, Nebraska · Completed
Hackensack University Medical Center - John Theurer Cancer Center
Hackensack, New Jersey · Active not recruiting
Columbia University
New York, New York · Completed
Weill Cornell Medicine
New York, New York · Completed
Wilmot Cancer Center/ University of Rochester
Rochester, New York · Active not recruiting
University of North Carolina - Chapel Hill Comprehensive Cancer Center
Chapel Hill, North Carolina · Active not recruiting
Duke Institute of Cancer/ Duke University
Durham, North Carolina · Recruiting
Sarah Cannon- Tennessee Oncology Nashville
Nashville, Tennessee · Active not recruiting
Fred Hutch Cancer Center
Seattle, Washington · Recruiting
Swedish Cancer Institute
Seattle, Washington · Completed
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin · Active not recruiting
Tom Baker Cancer Center/Alberta Health Services
Calgary, Alberta, Canada · Completed
Cross Cancer Institute / University of Alberta
Edmonton, Alberta, Canada · Completed
Vancouver General Hospital
Vancouver, British Columbia, Canada · Completed
Cancer Care Manitoba
Winnipeg, Manitoba, Canada · Active not recruiting
Memorial Hospital of Newfoundland
St. John's, Newfoundland and Labrador, Canada · Completed
Queen Elizabeth II Health Sciences Center
Halifax, Nova Scotia, Canada · Active not recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Active not recruiting
Maisonneuve-Rosemont Hospital
Montreal, Quebec, Canada · Completed
Royal Victoria Hospital / McGill University
Montreal, Quebec, Canada · Completed
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.